Later, McKie et al. [135] observed that Spry2 mRNA is downregulated in invasive prostate cancer cell lines as well as in clinically high-grade prostate cancers when compared to benign prostatic hyperplasia (BPH) and well-differentiated prostate tumors. This evidence concerns the gene SPRY2 and benign prostatic hyperplasia.